Skip to content
FrontierPicks

In the portfolio

KNSA · Kiniksa Pharmaceuticals International, plc

Conviction · Medium Distinct case Catalyst · Oncology & immunology

Updated ·

Against its published line

Above its line on the last close.

How to read this

The red mark is the published kill line — the price that would prove the thesis wrong. The dot is where the name closed on 30 October 2026; a dot left of the mark has closed through its line.

Distance is drawn on a square-root scale, so close calls get the room. Past 8% a row reads well clear, with a hollow dot to show the figure is off the drawn scale. Rows run tightest first.

How a pick is graded

Kill line

A weekly close below $80, under the $80.79 close of 22 October 2026, which would erase most of the gain since the 27 October 2026 report. Any company update lowering the $1.045–1.050 billion 2026 ARCALYST range would also break the case.

Open pick Medium conviction, opened at $72.98. Since then +28.6% against the S&P 500's −3.9% (+32.5 pp). Kill line at open: $70.00 (weekly close); graded by at the latest.

In the portfolio Since : +20.9%. See the portfolio.

Catalyst (in 3 days)

How picks are graded →

The thesis

Kiniksa Pharmaceuticals' case still rests on its third ARCALYST guidance raise of 2026, even after heavy executive share sales and a slip to an $88.34 close on 5 November 2026. The fourth-quarter report, estimated for about 24 February 2027, settles it: sales have to confirm the $1.045–1.050 billion range for 2026 ARCALYST net product revenue. ARCALYST treats recurrent pericarditis, a repeating inflammation of the sac around the heart, and it is the company's only commercial product.

The main new fact since the 2 November 2026 note is the scale of the selling. A Form 4 filed around 4 November 2026 shows Chairman and Chief Executive Sanj Patel sold 402,494 shares between 30 October 2026 and 3 November 2026, under a Rule 10b5-1 pre-arranged trading plan adopted on 30 July 2026. Other officers sold in the same days, and company news through 5 November 2026 shows no change to the guidance or the pipeline timetable.

The narrative is maturing: the 27 October 2026 report is widely known, analysts have largely updated their targets, and executives sold into the rally within a week of it. Third-quarter ARCALYST revenue was $286.0 million, against $180.9 million a year earlier (Kiniksa Q3 release, 27 October 2026).

Bullish and bearish views on Kiniksa Pharmaceuticals International, plc

The bull case on Kiniksa Pharmaceuticals International, plc (KNSA), in brief: Three guidance raises in one year. The bear case: Executives sold heavily after the report.

Bull case

  • Three guidance raises in one year. Kiniksa raised its 2026 ARCALYST range on 28 April 2026, 28 July 2026 and 27 October 2026. The range moved from $900–920 million to $1.045–1.050 billion, above the $996.1 million analyst estimate Benzinga cited on 27 October 2026.
  • Quarterly sales keep stepping up. ARCALYST revenue was $214.3 million in the first quarter of 2026, $243.6 million in the second and $286.0 million in the third (Kiniksa quarterly releases, 2026).
  • Analyst targets sit above the price. JPMorgan's $122 (30 October 2026), Wells Fargo's $110, Wedbush's $102 and Goldman Sachs' $101 (all 28 October 2026) exceed the $88.34 close of 5 November 2026. So do Citi's $100 and Canaccord's $98, both from 29 July 2026, and the $100.57 average target MarketBeat listed on 3 November 2026.
  • Most eligible patients are not yet treated. About 23% of roughly 14,000 multiple-recurrence pericarditis patients were on ARCALYST at 30 September 2026, up from about 21% at 30 June 2026. More than 5,450 prescribers have written the drug since launch (Kiniksa Q3 release).
  • Profit is growing faster than sales. ARCALYST collaboration profit rose 67% to $211.6 million in the third quarter, against 58% revenue growth, the chief financial officer said on the 27 October 2026 earnings call.

Bear case

  • Executives sold heavily after the report. Patel sold 220,170 shares on 3 November 2026 at an average of $93.27, for $20,535,255.90, and 89,433 shares on 2 November 2026 for $8,215,315.38 (Form 4; MarketBeat).
  • Chief Financial Officer Mark Ragosa sold 36,783 and John Paolini sold 18,413 on 2 November 2026 (Form 4; MarketBeat).
  • Regeneron keeps a large share. Kiniksa licenses ARCALYST from Regeneron and splits profits on it.
  • One product carries the company. Kiniksa does not expect Phase 3 data for KPL-387, its follow-on monthly injection, until the second half of 2027, or patient access before 2028 (Kiniksa, 27 October 2026).
  • Leadership is changing. Kiniksa appointed Moat as President and Chief Operating Officer on 22 October 2026, days before the report that reset expectations (Kiniksa, 22 October 2026).

Price setup

The shares closed at $88.34 on 5 November 2026, 9.5% below the $97.56 52-week closing high of 29 October 2026 and up 15.4% over three months (adjusted daily closes, Nasdaq). They had closed at $92.24 on 30 October 2026 and traded at $93.29 on 3 November 2026, according to MarketBeat. The latest close sits under the $89.86 intraday price Benzinga reported on 27 October 2026, when the shares were up 23.1% on the results.

The 14-day relative strength index, a momentum gauge running from 0 to 100, stood at 57.9 on 5 November 2026, which is neither stretched nor washed out. The nearest reference below is the $80.79 close of 22 October 2026, the last pre-report level the prior note used.

The observable crowding evidence is insider supply. Patel's plan dates from 30 July 2026 and Ragosa's from 29 July 2026, so both were adopted about three months before these sales. Earnings are not imminent, with the next report estimated for about 24 February 2027. The view that the shares keep most of the October repricing would be wrong on a weekly close below $80.

Catalysts, next 30 days

  • ~15 November 2026, est.: possible target updates from Citi and Canaccord. Their $100 and $98 targets date from 29 July 2026, and MarketBeat's 3 November 2026 summary still showed Canaccord at $98. Raises would line them up with the post-report increases.
  • No company event is confirmed in the next 30 days. Benzinga's events page lists no upcoming Kiniksa event, and no November 2026 conference announcement was found. Kiniksa presented at Jefferies' London healthcare conference in November 2025.
  • 31 December 2026: company target for starting the KPL-1161 Phase 1 trial. This shows whether the pipeline keeps to the timeline Kiniksa stated on 27 October 2026.
  • ~11 January 2027, est.: J.P. Morgan Healthcare Conference. Kiniksa presented there in January 2026, and an appearance would be the first update on fourth-quarter demand.
  • ~24 February 2027, est.: fourth-quarter and full-year 2026 results. The report settles whether sales met the $1.045–1.050 billion range and sets the first 2027 ARCALYST guidance.

What would change the view

The case breaks if Kiniksa lowers the $1.045–1.050 billion range, or if fourth-quarter revenue falls short of it. A slower 2027 ARCALYST growth outlook in the first 2027 guidance would also weaken it. So would a company update moving KPL-387 Phase 3 data beyond the second half of 2027, because that extends dependence on one licensed product.

Further executive sales outside Rule 10b5-1 plans would change the reading of the current selling, since those would reflect a decision made at current prices. On price, a weekly close below $80, under the $80.79 close of 22 October 2026, would erase most of the gain since the 27 October 2026 report.

What it trades with

Kiniksa's largest recent move came from its own results. The shares rose 23.1% intraday on 27 October 2026 while the S&P 500 rose 0.5% (Benzinga). One session is too small a sample to measure how the shares track the market. The company's sales and guidance reports are the events the case turns on, and a 2027 guidance range below the 2026 growth pace would show the frame is wrong.

Regeneron is the licensor and shares ARCALYST profits, as Kiniksa's 10-Q shows, so the commercial link runs through that collaboration.

Notes

  • Kiniksa's guidance covers ARCALYST net product revenue only; total company revenue is a separate figure.
  • Kiniksa is an Ireland-domiciled plc whose Class A ordinary shares trade on Nasdaq; other share classes are not publicly traded.
  • Kiniksa licenses ARCALYST from Regeneron and shares profits on it, so net product revenue is not the same as profit retained by Kiniksa.
  • Kiniksa expects KPL-387 Phase 3 data in the second half of 2027 and patient access in 2028 or 2029; both dates are company expectations and neither is an approval.

Sources

Related · shared themes

See also · stocks to watch